peptides for libido

updated

one peptide approved by the FDA for low libido in women. central melanocortin, not vascular.

one peptide on this page has an fda libido-related indication. pt-141, branded vyleesi, approved june 21 2019 for acquired generalized hypoactive sexual desire disorder in premenopausal women. 1,267 women randomised across reconnect 1 and 2, with the fsfi desire score up 0.35 points more than on placebo. it acts centrally through melanocortin receptors, not vascular smooth muscle, which is why it works on the desire axis where pde5 drugs do not, and why it has its own side-effect profile (transient blood-pressure rise, nausea, focal hyperpigmentation).

everything else in the libido category sits at less mature evidence. kisspeptin-family research is real and published in jama network open, but the hsdd and ivf trials used kisspeptin-54 while vendors sell kp-10. oxytocin was the first peptide hormone ever synthesized but only obstetric labels exist. hcg, gonadorelin, and triptorelin are reproductive-axis drugs that get reclassified as libido peptides without the indication to match. enclomiphene, estradiol, and menotropins also belong in the reproductive-axis lane; hormone or fertility endpoints do not establish desire outcomes.

tadalafil has direct erectile-function evidence. erection and desire are different endpoints.

the direct libido cluster.

compounds whose published evidence or mechanism sits closest to sexual desire and arousal rather than general hormone support.

  • pt-141 (tier A) · bremelanotide. fda-approved as vyleesi june 21 2019 for hsdd in premenopausal women. reconnect 1 + 2 randomised 1,267 women. · mac hadley's lab at university of arizona discovered the arousal effect in the 1990s during melanotan-ii self-administration work. dorr 1996 phase-1: 9 of 10 male subjects developed erections after subcutaneous injection. palatin pivoted intranasal-ed off the program in 2007 over blood pressure, then carried the subcutaneous female-hsdd indication through reconnect 1 + 2 (1,267 women randomised) to vyleesi fda approval on june 21 2019. the fsfi desire score rose 0.35 points more than on placebo. the only fda-approved peptide for low libido anywhere on the site.
  • melanotan-ii (tier C) · non-selective melanocortin agonist with pigment and arousal effects. parent compound from which bremelanotide was derived. · the arousal effect documented in the early melanotan-ii literature is what pt-141 was later developed from as the second-generation cleaner analog. tanning and off-target safety concerns kept melanotan-ii out of drug development. still sold in gray-market channels.
  • kisspeptin-10 (tier B) · kp-10. 10-amino-acid c-terminal fragment of kisspeptin. master hpg-axis trigger. · the welch lab at pennsylvania state hershey discovered the parent gene in 1996 as a melanoma metastasis suppressor and named it kiss1 after hershey kisses chocolates. the reproductive role wasn't recognized until 2003. imperial college london (waljit dhillo) ran the strongest hsdd trials, jama network open, with fmri and tumescence endpoints, all using kp-54. kp-54 ivf-trigger work reports ~23% clinical pregnancy with dramatically reduced ohss vs hcg. vendors sell kp-10 on kp-54 trial data. that is a real bait-and-switch. see the claim-check below.
  • oxytocin (tier B) · cyclic nonapeptide, fda-approved (pitocin) for obstetric use only. · vincent du vigneaud at cornell synthesized oxytocin in 1953, the first peptide hormone ever chemically synthesized. nobel prize in chemistry 1955. seventy years later the only fda-approved indications are still labor induction and postpartum bleeding (pitocin, 1962). phase-2 work on autism, ptsd, social anxiety, anorgasmia. social and sexual endpoints in the literature do not track the popular-press nickname.

hormone support is not the same claim.

compounds that affect reproductive signaling, fertility, or endocrine axes. libido shows up in user discussion. the published indications target gonadal axis function, not desire.

  • hcg (tier S) · lh analog. fda-approved for hypogonadotropic hypogonadism, fertility induction, and cryptorchidism. brand names: pregnyl, novarel, ovidrel. · real drug with serious indications. labeled use is reproductive-axis management in clinical medicine, not a generic libido peptide. testosterone-axis preservation during exogenous androgens is the off-label case in the men's-health community.
  • gonadorelin (tier C) · synthetic gnrh. 2-4 minute plasma half-life. pulsatile dosing defines the pharmacology. · clinically real and historically used for pulsatile fertility induction. oversold by hrt clinics as a simple hcg substitute. the pulse biology matters: continuous gnrh exposure desensitizes the axis (which is exactly how triptorelin suppresses gonadal function).
  • triptorelin (tier C) · gnrh agonist. fda-approved as trelstar for prostate cancer and as triptodur for central precocious puberty. · an endocrine drug with serious oncology and pediatric indications, not a casual libido tool. continuous exposure suppresses the axis it appears to stimulate at first dose. same molecule, opposite effect depending on pattern.
  • Enclomiphene (tier B) · Enclomiphene is the trans isomer of clomiphene and an oral selective estrogen-receptor modulator studied in men with secondary hypogonadism. Its strongest results are hormone and sperm surrogate endpoints. · Oral enclomiphene can raise endogenous testosterone, LH, and FSH while maintaining sperm concentration over a short trial. It has not established symptom relief, fertility or live-birth benefit, or an approved long-term treatment role.
  • Estradiol (tier S) · Estradiol is the principal intracellular human estrogen and an FDA-approved drug across multiple distinct formulations. Oral, transdermal, vaginal, valerate, and cypionate records are not interchangeable. · Estradiol is established therapy for labeled menopause and hypoestrogenism indications. The useful question is not whether estradiol works in the abstract, but which molecule, route, formulation, population, and risk context the claim describes.
  • Menotropins (tier S) · Current US Menopur is a subcutaneous urinary menotropins product for developing multiple follicles and pregnancy in ovulatory women during an ART cycle. It is fertility medicine, not sexual-performance or hormone-optimization treatment. · Monitored ART trials support Menopur's current female indication and quantify pregnancy, live-birth, OHSS, and multiple-pregnancy outcomes. Historical male hMG plus hCG findings do not create a current Menopur male indication or regimen.
  • tadalafil (tier S) · this is cialis, the erection pill. the same molecule does three jobs. it helps men with erectile dysfunction get an erection, it eases the urinary symptoms of an enlarged prostate, and at 40 mg, under the name adcirca, it treats high blood pressure in the arteries of the lungs. a pde5 inhibitor with a 17.5-hour mean half-life, two decades of approved human trials, and a research channel selling two other molecules under its name. · it is cialis, the erection pill. it is approved for erection problems, for the urinary symptoms of an enlarged prostate, and at the higher 40 mg dose, as adcirca, for high blood pressure in the arteries of the lungs. the approved evidence is enormous and mostly positive. the trouble starts at the label on the research vial, where the same word covers two other molecules.

specific-question reference.

which peptide has an fda-approved libido indication?

one. pt-141, as bremelanotide/vyleesi, approved june 21 2019 for acquired generalized hypoactive sexual desire disorder in premenopausal women. reconnect 1 and 2 randomised 1,267 women. the fsfi desire score rose 0.35 points more than on placebo. the indication is specific. it is not a universal libido prescription, and it is not approved in men.

is kp-10 the same as kp-54 in the published trials?

no. this is the bait-and-switch in the category. the imperial college london trials (waljit dhillo, jama network open) that produced the 56% tumescence-increase reading and fmri changes used kisspeptin-54. the ivf-trigger work also used kp-54 (~23% clinical pregnancy with lower ohss vs hcg). gray-market vendors sell kp-10. they share the c-terminal receptor-binding motif, but half-life and trial portfolio differ. kp-10 has its own mechanistic literature (george et al. edinburgh group) but is not the molecule from the headline hsdd readings.

is pt-141 the same as melanotan-ii?

no. they share melanocortin biology, but pt-141 was developed through palatin technologies as a drug product with reconnect 1 + 2 and an fda label. melanotan-ii is a broader non-selective receptor agonist with tanning and arousal effects but no drug-development pedigree.

where do hcg, gonadorelin, and triptorelin fit?

reproductive-axis drugs. fertility induction, testosterone-axis preservation, gonadal suppression in oncology and pediatrics. libido shows up in user discussion but is an indirect, person-specific endpoint, not an indication.

why is oxytocin hard to summarize as a libido peptide?

the only fda labels are obstetric (pitocin, 1962). seventy years of off-label phase-2 work covers autism, ptsd, social anxiety, anorgasmia. context and dose shift the effect pattern. the popular-press nickname does not compress cleanly.

what the safety literature reports.

what does the pt-141 / vyleesi label-defined safety profile look like?

transient blood-pressure increase (the reason palatin abandoned the intranasal-ed program in 2007 and re-engineered for subcutaneous female hsdd), nausea, vomiting, headache, focal hyperpigmentation. label contraindication: uncontrolled hypertension or known cardiovascular disease.

what is the safety difference with melanotan-ii?

melanotan-ii is a non-selective melanocortin agonist with the same nausea and blood-pressure signal plus broader pigment effects, including new and changing nevi reported in case literature. no fda label, no formal safety review, no controlled long-term human trial.

what safety issue matters for kisspeptin-family compounds?

the published imperial college kp-54 trials report a clean acute safety profile in small-n single-dose work. long-term and high-dose data are not in the published record. kp-10 has its own profile that is not interchangeable with kp-54.

what safety issue matters for reproductive-axis compounds?

hormonal feedback. continuous gnrh exposure desensitizes the axis (the mechanism by which triptorelin suppresses gonadal function). pulsatile dosing stimulates it. same molecule, opposite effect depending on pattern. that is clinical endocrinology, not search-result territory.

related comparisons

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.